Antisense Oligonucleotide VLA-4 Targeting for MS Lesion Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple sclerosis, particularly relapsing forms, are limited in effectively inhibiting the accumulation of new active brain lesions, reducing the volume of gadolinium-enhancing lesions, and managing disease progression, with existing therapies often associated with significant side effects and variable efficacy.
Innovation Solution
Administration of a pharmaceutical composition containing a therapeutically effective amount of an oligonucleotide with a specific phosphorothioate diester backbone and 2′-O-(2-methoxyethyl) modified ribonucleosides, targeting VLA-4 integrin to reduce leukocyte migration into the CNS, thereby inhibiting lesion formation and disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for multiple sclerosis are used, then disease progression can be managed to some extent, but the accumulation of new active brain lesions continues and significant side effects occur
Solution Approach 1:
The patent employs antisense oligonucleotides with specific chemical modifications (phosphorothioate backbone, 2'-O-methoxyethyl groups) to change the molecular parameters of the therapeutic agent, enabling targeted inhibition of VLA-4 integrin while improving safety profile and reducing side effects compared to conventional MS treatments
Solution Approach 2:
The antisense oligonucleotide acts as an intermediary molecule that binds to VLA-4 integrin mRNA, preventing its translation into functional protein. This intermediary mechanism blocks leukocyte migration into the CNS without requiring direct immunosuppression, thereby reducing side effects while maintaining disease progression management
2Manufacturing precision
If existing therapies are administered to reduce gadolinium-enhancing lesions, then some lesion volume reduction is achieved, but efficacy varies significantly and treatment response is inconsistent
Solution Approach 1:
The patent targets a specific molecular pathway (VLA-4 integrin) rather than employing broad immunosuppression. By segmenting the therapeutic approach to focus on a single key mediator of leukocyte migration, the treatment achieves more consistent and predictable lesion volume reduction with reliable efficacy across patients
Solution Approach 2:
The patent replaces conventional immunosuppressive mechanisms with a targeted molecular inhibition approach using antisense oligonucleotides. This substitution provides more precise control over the therapeutic effect, leading to consistent gadolinium-enhancing lesion volume reduction with reliable treatment response
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly reduces the number and volume of new active brain lesions, decreases gadolinium-enhancing lesions, and slows disease progression, as demonstrated by MRI measurements, with a favorable safety profile and reduced side effects compared to conventional treatments.
Implementation Method 1
antisense oligonucleotides (AS-ONs) are short stretches of nucleotides or nucleotide derivatives that are complementary to a region of targeted RNA and can specifically suppress expression and other aspects such as processing of that particular transcript
Implementation Method 2
each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester
Implementation Method 3
the nucleotides at the positions 1 to 3 from the 5′ end are 2′-O-(2-methoxyethyl) modified ribonucleosides
Data Source
AI summary
A method for treating a patient suffering from multiple sclerosis, particularly a relapsing form of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE 1 to the patient, thereby treating the patient.